Gilteritinib

What is Gilteritinib?

Gilteritinib is a highly selective Fms-like tyrosine kinase 3 (FLT3) inhibitor, marking a significant advancement in the treatment of acute myeloid leukemia (AML). It is a targeted therapy specifically designed to combat certain forms of this aggressive blood cancer. Approved for use in adult patients, Gilteritinib offers a crucial option for those whose disease harbors specific genetic mutations.

This medication belongs to a class of drugs known as kinase inhibitors, which work by blocking the activity of specific enzymes (kinases) that are overactive in cancer cells. In the context of AML, Gilteritinib is particularly effective against cells with an FLT3-mutated acute myeloid leukemia (FLT3-AML), a subtype of the disease known for its poor prognosis and resistance to conventional chemotherapy.

How Does it Work?

The mechanism of action for Gilteritinib centers on its ability to selectively inhibit the FLT3 receptor tyrosine kinase. Mutations in the FLT3 gene, particularly internal tandem duplications (ITDs) and tyrosine kinase domain (TKD) point mutations, are common in AML and lead to constitutive activation of the FLT3 receptor. This uncontrolled activation drives the proliferation and survival of leukemic cells.

As a potent FLT3 inhibitor, Gilteritinib binds to and blocks the mutated FLT3 receptor, thereby disrupting the downstream signaling pathways essential for cancer cell growth and survival. By inhibiting this crucial enzyme, Gilteritinib induces apoptosis (programmed cell death) in the leukemic cells, effectively reducing the tumor burden. Its targeted nature allows for a more precise attack on cancer cells while minimizing damage to healthy cells compared to traditional chemotherapy, although side effects can still occur.

Medical Uses

The primary medical use of Gilteritinib is in the treatment of adult patients with acute myeloid leukemia (AML) that is FLT3-mutated, as detected by an FDA-approved test. It is specifically indicated for patients with relapsed or refractory AML, meaning the disease has returned after initial treatment or has not responded to previous therapies. This targeted approach represents a significant step forward for patients who previously had limited treatment options.

Before initiating treatment with Gilteritinib, it is essential for patients to undergo genetic testing to confirm the presence of an FLT3 mutation. This ensures that the therapy is appropriately targeted to those who are most likely to benefit, aligning with the principles of precision medicine in oncology.

Dosage

The recommended starting dose of Gilteritinib is typically 120 mg orally once daily. It is administered continuously until the patient experiences unacceptable toxicity or disease progression. The medication can be taken with or without food. It is crucial to follow the prescribing physician's instructions carefully regarding dosage and administration.

If a dose is missed, it should be taken as soon as possible on the same day. However, if it's almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule resumed. Patients should never take two doses to make up for a missed dose. Dose adjustments may be necessary based on individual patient response and the occurrence of side effects, as determined by a healthcare professional.

Side Effects

Like all medications, Gilteritinib can cause side effects. Common side effects include fatigue, elevated liver enzymes (ALT and AST), diarrhea, nausea, constipation, muscle pain (myalgia), joint pain (arthralgia), and cough. Most of these are manageable and can be addressed with supportive care.

More serious side effects, though less common, can occur. These include differentiation syndrome, which is a potentially life-threatening condition associated with FLT3 inhibitors and characterized by fever, respiratory distress, fluid retention, and kidney dysfunction. Other serious risks include posterior reversible encephalopathy syndrome (PRES), prolonged QT interval (an electrical activity issue in the heart), pancreatitis, and embryonic-fetal toxicity. Patients should report any unusual or severe symptoms to their healthcare provider immediately.

Drug Interactions

Gilteritinib is metabolized by the enzyme CYP3A, and its effectiveness or safety can be affected by other drugs that interact with this enzyme. Strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin) can increase Gilteritinib exposure, potentially leading to increased side effects. Conversely, strong CYP3A inducers (e.g., rifampin, phenytoin) can decrease Gilteritinib exposure, reducing its efficacy.

Additionally, Gilteritinib is a substrate of P-glycoprotein (P-gp), and co-administration with P-gp inhibitors or inducers may alter its plasma concentrations. Care should also be taken when Gilteritinib is administered with drugs known to prolong the QT interval, as this could increase the risk of cardiac arrhythmias. Patients must inform their healthcare providers about all medications, supplements, and herbal products they are taking to avoid potential drug interactions.

FAQ

• What is FLT3-mutated AML?

  FLT3-mutated AML is a subtype of acute myeloid leukemia where the cancer cells have a mutation in the FLT3 gene, leading to uncontrolled cell growth. This mutation is a common driver of the disease and is associated with a more aggressive form of AML.

• How is Gilteritinib administered?

  Gilteritinib is an oral medication, taken as a tablet once daily, with or without food. It is crucial to take it at approximately the same time each day.

• Can Gilteritinib cure AML?

  While Gilteritinib can lead to significant reductions in leukemic cells and improve outcomes for patients with FLT3-mutated relapsed or refractory AML, it is not always a cure. It is a powerful targeted therapy that can achieve remission and prolong survival, but long-term monitoring and potential further treatment may be necessary.

• What should I do if I miss a dose?

  If you miss a dose, take it as soon as you remember on the same day. However, if it is less than 12 hours until your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses to make up for a missed one.

Products containing Gilteritinib are available through trusted online pharmacies. You can browse Gilteritinib-based medications at ShipperVIP or Medicenter.

Summary

Gilteritinib represents a vital treatment option for adult patients battling FLT3-mutated acute myeloid leukemia (AML) that has relapsed or is refractory to previous treatments. As a targeted tyrosine kinase inhibitor, it specifically blocks the mutated FLT3 receptor, offering a more precise approach to combating this aggressive blood cancer. While effective, it is essential for patients to be carefully monitored for potential side effects and drug interactions. Always consult with a healthcare professional to determine if Gilteritinib is the appropriate treatment for your specific condition and to understand its full implications.